Regeneron Pharmaceuticals, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDRegeneron Pharmaceuticals, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is moderate (RS Rating: 78), indicating performance broadly in line with the market. Earnings contraction of 2% provides fundamental context to the price action. Momentum will need to be maintained above the 50-day moving average to sustain this leadership phase.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $776.60 | +0.65% | ABOVE |
| 50 SMA | $770.40 | +1.46% | ABOVE |
| 100 SMA | $718.84 | +8.74% | ABOVE |
| 150 SMA | $669.96 | +16.67% | ABOVE |
| 200 SMA | $638.63 | +22.40% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is REGN in an uptrend right now?
REGN has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, REGN is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is REGN overbought or oversold?
REGN's RSI (14) is 49. The stock is in neutral territory, neither overbought nor oversold.
Is REGN outperforming the market?
REGN has a Relative Strength (RS) Rating of 78 out of 99. REGN is performing about average compared to the market.
Where is REGN in its 52-week range?
REGN is trading at $781.67, which is 95% of its 52-week high ($821.11) and 89% above its 52-week low ($476.49).
How volatile is REGN?
REGN has a Beta of 0.58 and 52-week volatility of 41%. It's less volatile than the S&P 500 - generally more stable.